Fosinopril Versus Amlodipine Comparative Treatments Study: A Randomized Trial to Assess Effects on Plasminogen Activator Inhibitor-1
The DOI matches its Crossref record.
Abstract
Background — ACE inhibitors and calcium antagonists may modulate fibrinolysis. We conducted a randomized controlled trial to assess the effects of these drugs on plasminogen activator inhibitor-1 (PAI-1) antigen, an inhibitor of fibrinolysis. Methods and Results — Participants with hypertension and type 2 diabetes mellitus (n=96, 51% black) were randomized after an initial 4 weeks of placebo to double-blind 20 or 40 mg fosinopril or 5 or 10 mg amlodipine daily for 4 weeks in a fixed-dose regimen. After 4 weeks of placebo washout, the patients received 4 weeks of crossover treatments. After treatment with placebo, systolic and diastolic blood pressure were 143±2 and 86±1 mm Hg and plasma PAI-1 was 43.4±2.3 ng/mL. Amlodipine achieved a greater systolic and diastolic blood pressure reduction than fosinopril (10 mm Hg versus 8 mm Hg, P =0.029, and 5 mm Hg versus 3 mm Hg, P =0.040, respectively) but tended to increase PAI-1, whereas fosinopril tended to decrease PAI-1 (5.4±3.6 versus −3.8±2.5 ng/mL, P =0.045). The PAI-1 changes depended on drug dose (6.5±6.1 and 3.4±3.9 ng/mL with amlodipine 10 and 5 mg, respectively, and −0.4±3.1 and −7.4±4.0 ng/mL with fosinopril 20 and 40 mg, respectively, P for trend 0.024). No significant differences between fosinopril and amlodipine were found for short-term changes in tissue plasminogen activator antigen, fibrinogen, C-reactive protein, and interleukin-6. The findings were similar in black and white participants. Conclusions — Short-term treatment with fosinopril significantly reduced PAI-1 compared with amlodipine in a dose-dependent fashion. This effect, which was independent of blood pressure reduction, may account for the improved clinical outcomes achieved with ACE inhibitors compared with calcium antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Minireview: Adiposity, Inflammation, and Atherogenesis
Lyon, C. J., Law, R. E., & Hsueh, W. A. (2003) · Endocrinology · doi:10.1210/en.2003-0285 · Cited by 761
Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.649939 · Cited by 385
Rahman, M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.936 · Cited by 340
C‐Reactive Protein (CRP)‐Lowering Agents
Prasad, K. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00033.x · Cited by 272
Nicklas, B. J. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040769 · Cited by 259
Metadata
- Authors
- Pahor, M., Franse, L. V., Deitcher, S. R., Cushman, W. C., Johnson, K. C., Shorr, R. I., Kottke-Marchant, K., Tracy, R. P., Somes, G. W., & Applegate, W. B.
- Venue
- Circulation
- Published
- 2002-01-29
- Volume
- 105
- Issue
- 4
- Pages
- 457-461
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2036585955
- Cited by
- 67
- References
- 0
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fosinopril Versus Amlodipine Comparative Treatments Study: A Randomized Trial to Assess Effects on Plasminogen Activator Inhibitor-1. https://app.cochat.ai/papers/10.1161/hc0402.102929
- The paper
- Pahor, M., Franse, L. V., Deitcher, S. R., Cushman, W. C., Johnson, K. C., Shorr, R. I., Kottke-Marchant, K., Tracy, R. P., Somes, G. W., & Applegate, W. B. (2002). Fosinopril Versus Amlodipine Comparative Treatments Study: A Randomized Trial to Assess Effects on Plasminogen Activator Inhibitor-1. Circulation. https://doi.org/10.1161/hc0402.102929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.